Feature | March 27, 2013

Biotronik Iforia is World’s First DF4 ICD/CRT-D Approved for MRI

First implantations of the device taking place worldwide

Biotronik Iforia ICD/CRT-D CE-Approval

March 27, 2013 — Biotronik received CE mark for its most advanced ICD/CRT-D (implantable cardioverter defibrillator/cardiac resynchronization therapy device) series. Iforia is the world’s first DF4 ICD/CRT-D series approved for MRI (magnetic resonance imaging). In addition it contains one of the world’s smallest ICDs, the Iforia single chamber ICD.

Aside from featuring ProMRI technology, which allows patients to undergo potentially life-saving MRI scans, Iforia also includes the industry standard DF4 connector system, which is designed to simplify and shorten the implantation procedure. The DF4 connector combines the traditional three connectors into one, allowing for a more convenient implantation procedure without compromising safety.

One of the first implanters, Ching Chi Keong, M.D., of National Heart Centre Singapore, said, “With the Iforia series I can provide my patients with a small and highly reliable ICD and CRT-D series. It includes an impressive range of state-of-the-art innovations including ProMRI and home monitoring. In addition the DF4 technology simplifies the implantation procedure, while the small size of the device makes it more comfortable for the patient and also leads to a better cosmetic result.”

The Iforia series is one of the smallest ICDs and CRT-Ds on the market. In addition the Iforia single chamber ICD has a longevity of more than 11 years and the Iforia CRT-D of more than seven years. This allows for a low replacement rate, benefitting both patients and the healthcare system.

“Safety and reliability are the foundation of all of our new technologies and innovations,” said Christoph Böhmer, president international of Biotronik. “Iforia offers enhanced diagnostic possibilities with the highest reliability and unsurpassed longevity... The new Iforia series combined with ProMRI and Biotronik Home Monitoring offers physicians and patients the best combination of reliability and innovation.”

The European market release of the Iforia series is expected in mid-2013. The first implanters of Biotronik's Iforia ICDs and CRT-Ds are:

  • Prof. Dr. Steffen Behrens, Vivantes Humboldt Hospital Berlin, Germany;
  • Ching Chi Keong, M.D., National Heart Centre Singapore, Singapore;
  • Dr. Thomas Faber, University Heart Centre Freiburg, Germany;
  • Prof. Dr. Stephan B. Felix and Dr. Mathias Busch, University Hospital Greifswald, Germany;
  • Dr. Peter Lercher and Dr. Günther Prenner, LKH-University Clinic Graz, Austria;
  • Abdulmohsen al Musaad, M.D., National Guard Health Affairs Hospital, Riyadh, Saudi Arabia;
  • Dr. Antti Ylitalo and Dr. Tuomas Paana, Satakunta Central Hospital, Pori, Finland.


For more information: www.biotronik.com

Related Content

EpiAccess System, EpiEP, Mount Sinai New York, epicardial access
News | Ablation Systems| August 22, 2016
August 22, 2016 — The Mount Sinai Hospital is the first site in the New York metropolitan area to pioneer a new appro
warfarin, long-term stability, atrial fibrillation, DCRI study, Sean Pokorney
News | Antiplatelet and Anticoagulation Therapies| August 16, 2016
August 16, 2016 — Warfarin prescribed to prevent strokes in...
Sponsored Content | Videos | Inventory Management| August 15, 2016
Pacemakers, stents and bandages — keeping tracking of what is on hand and accurately capturing charges can be a chall
News | EP Lab| August 12, 2016
August 12, 2016 — Electrophysiology ablation navigation system company Stereotaxis Inc.
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, most popular content, most popular stories, DAIC

The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves. 

Feature | August 05, 2016 | Dave Fornell
 
Watchman, left atrial appendage closure, LAA occluder

An illustration of a Watchman transcatheter LAA occluder being implanted.

Feature | Left Atrial Appendage (LAA) Occluders| August 01, 2016 | Dave Fornell
Patients with atrial fibrillation (AF or Afib) are high risk for stroke due to the formation of thrombus emboli in th
CMS, Overall Hospital Quality Star Rating, national distribution, quailty of care
News | Business| July 26, 2016
July 25, 2016 — The Centers for Medicare and Medicaid Services (CMS) announced that it expects to launch its new Over
pros and cons of new anticoagulation therapies, anticoagulants, dabigatran, Pradaxa, novel oral anticoagulants, NOACs, rivaroxaban, Xarelto, apixaban, Eliquis
Feature | Antiplatelet and Anticoagulation Therapies| July 26, 2016 | Heidi Olson, Pharm.D
With the recent introduction of several novel oral...
Overlay Init